Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Summary

PF-06700841 is a dual Tyrosine kinase 2 (TYK2) Janus kinase 1 (JAK1) inhibitor that is being developed for oral treatment of adult patients with Inflammatory Bowel Disease (IBD).This open-label study will evaluate the pharmacokinetics of PF-06700841 following single oral doses of immediate release (IR) and modified release (MR) tablets in healthy, adult participants under fasted conditions. This is an open label, single dose, randomized, 2 period, 2- sequence crossover study in a single cohort of approximately 8 (minimum 6) healthy participants.

Timeline

Start

2019-01-07

Primary completion

2019-04-03

Completion

2019-04-03

Drugs

Indications

No indication recorded.